Nothing Special   »   [go: up one dir, main page]

AU1070901A - Method of treating cells of the prostate prophylactically or therapeutically - Google Patents

Method of treating cells of the prostate prophylactically or therapeutically

Info

Publication number
AU1070901A
AU1070901A AU10709/01A AU1070901A AU1070901A AU 1070901 A AU1070901 A AU 1070901A AU 10709/01 A AU10709/01 A AU 10709/01A AU 1070901 A AU1070901 A AU 1070901A AU 1070901 A AU1070901 A AU 1070901A
Authority
AU
Australia
Prior art keywords
prophylactically
prostate
therapeutically
treating cells
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10709/01A
Inventor
Joseph T Bruder
Ping Chen
C. Richter King
Wayne M. Kirkman
Imre Kovesdi
Stephen C. Ransom
Thomas J Wickham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genvec Inc
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of AU1070901A publication Critical patent/AU1070901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU10709/01A 1999-09-23 2000-09-22 Method of treating cells of the prostate prophylactically or therapeutically Abandoned AU1070901A (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US15574299P 1999-09-23 1999-09-23
US60155742 1999-09-23
US16531899P 1999-11-12 1999-11-12
US60165318 1999-11-12
US18057300P 2000-02-04 2000-02-04
US60180573 2000-02-04
US20061800P 2000-04-28 2000-04-28
US60200618 2000-04-28
PCT/US2000/026101 WO2001021217A2 (en) 1999-09-23 2000-09-22 Method of treating cells of the prostate prophylactically or therapeutically

Publications (1)

Publication Number Publication Date
AU1070901A true AU1070901A (en) 2001-04-24

Family

ID=27496208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10709/01A Abandoned AU1070901A (en) 1999-09-23 2000-09-22 Method of treating cells of the prostate prophylactically or therapeutically

Country Status (2)

Country Link
AU (1) AU1070901A (en)
WO (1) WO2001021217A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453537A1 (en) 2001-12-12 2004-09-08 FH Faulding & Co. Limited Composition for viral preservation
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
KR101683964B1 (en) * 2014-05-29 2016-12-09 연세대학교 산학협력단 An expression vector comprising nucleic acid downregulating Daxx, TRAIL gene and nucleic acid downregulating Bcl-xL
AU2017223589B2 (en) 2016-02-23 2023-08-03 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0886524A2 (en) * 1996-03-01 1998-12-30 Chiron Corporation Delivery of therapeutic agents to the prostate
US6037461A (en) * 1997-05-20 2000-03-14 Thomas Jefferson University FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
AU3454799A (en) * 1998-03-30 1999-10-18 Baylor College Of Medicine Regulated apoptosis using chemically induced dimerization of apoptosis factors

Also Published As

Publication number Publication date
WO2001021217A3 (en) 2001-08-09
WO2001021217A2 (en) 2001-03-29

Similar Documents

Publication Publication Date Title
AU6367099A (en) Improved process for water treatment
AU2301699A (en) System for the treatment of wafers
AU1387401A (en) Coating process
AU7982498A (en) Water treatment process
AU1878601A (en) Enzyme
AU2882299A (en) Anti-asthma therapy
AU5089400A (en) Arthritis treatment
AU1538901A (en) Polymersation process
AU6298400A (en) Metal surface treatment
AU4981600A (en) Snowmaking process
AU7126900A (en) Enzyme inhibitors
AU7416700A (en) Insulating shaped body and method for producing the same
AU7363000A (en) Method for reducing the risk of cancer
AU2482400A (en) Advanced treatment for produced water
AU1070901A (en) Method of treating cells of the prostate prophylactically or therapeutically
AU1715100A (en) Biochemically enhanced thermophilic treatment process
AU6006800A (en) Treating cells
AU4632800A (en) Process optimation
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU7127100A (en) Enzyme inhibitors
AU2924400A (en) Plant treatment method
AU4598400A (en) Method of treatment
AU4367900A (en) Carbohydrate-modifying enzymes
AU5969300A (en) Pressure treatment of cells
AU6088099A (en) Water treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase